0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA | March 27, 2013|

This Week in JAMA FREE

JAMA. 2013;309(12):1201. doi:10.1001/jama.2012.145324.
Text Size: A A A
Published online

CHELATION THERAPY AND CARDIOVASCULAR EVENTS

For decades, chelation therapy has been promoted as a treatment for atherosclerosis—with no proof of efficacy. In a randomized, double-blind, placebo-controlled trial that enrolled 1708 patients with a history of myocardial infarction (median, 4.6 years prior), Lamas and colleagues found that compared with placebo, use of an intravenous EDTA-based chelation regimen—40 infusions over 1 to 3 years—modestly reduced the risk of a composite of adverse cardiovascular outcomes during a median follow-up of 55 months. In an editorial, Nissen discusses aspects of the trial design and execution that compromise the reliability of the evidence generated. An editorial by Bauchner and colleagues describes evaluation of the study at JAMA and factors considered in the publication decision.

MAINTENANCE THERAPY FOR NON-CF BRONCHIECTASIS

Two articles in this issue report results of clinical trials that investigated long-term macrolide maintenance therapy for patients with non–cystic fibrosis (non-CF) bronchiectasis and frequent pulmonary exacerbations. Altenburg and colleagues randomly assigned 83 patients to receive either azithromycin (250 mg daily) or placebo for 1 year and found that patients receiving azithromycin had fewer infectious exacerbations. Serisier and colleagues randomly assigned 117 patients to receive either erythromycin (400 mg, twice daily) or placebo for 12 months and found a modest decrease in pulmonary exacerbations among patients receiving erythromycin. In an editorial, Elborn and Tunney discuss the need to balance benefits of long-term macrolide therapy with concerns regarding development of antibiotic resistance.

PDE-5 INHIBITION IN PATIENTS WITH HEART FAILURE

Experimental and clinical evidence suggest phosphodiesterase-5 (PDE-5) inhibition may enhance cardiovascular function in patients with heart failure with preserved ejection fraction. In a randomized, placebo-controlled trial involving 216 patients with heart failure and preserved ejection fraction, Redfield and colleagues found that PDE-5 inhibition with sildenafil did not improve patients' exercise capacity or clinical status.

See Article

CLINICIAN'S CORNER IMMUNOTHERAPY FOR ALLERGIC RHINITIS, ASTHMA

Sublingual immunotherapy is approved in Europe but not the United States. However, some US physicians use aqueous allergens, off-label, for sublingual desensitization. In a systematic review, Lin and colleagues identified 63 randomized trials (involving 5131 child and adult participants) of sublingual immunotherapy for allergic rhinoconjunctivitis or asthma and found moderate-grade evidence to support the effectiveness of sublingual immunotherapy for these conditions. High-quality studies are needed to determine optimal dosing strategies. In an editorial, Nelson discusses many unanswered questions regarding the efficacy of sublingual immunotherapy.

See Article and Editorial

JAMA CLINICAL CHALLENGE

A patient with HIV infection who has been taking antiretroviral medication for 1 year presents with lipodystrophy confined to the cervicodorsal region. Laboratory findings, including complete metabolic and endocrine panels, are normal. What would you do next?

See Article

MEDICAL NEWS & PERSPECTIVES

More than 50 years after initiating newborn screening for congenital disorders, the approach remains one of the United States' most successful public health interventions.

See Article

VIEWPOINTS

A systematic plan for firearms law reform

See Article

Mental illness and gun law reform

See Article

Economics of genomic medicine

See Article

Crossing the omic chasm

See Article

A PIECE OF MY MIND

“While the general public is shocked at the wholesale trauma guns bring at Columbine, Aurora, or Sandy Hook, we in medicine are not as surprised.” From “The NRA Let Me Down.”

See Article

EDITOR'S AUDIO SUMMARY

Dr Fontanarosa summarizes and comments on this week's issue. Go to www.jama.com

AUTHOR IN THE ROOM TELECONFERENCE

Join Phillip Boiselle, MD, Wednesday April 17, 2013, from 2 to 3 PM eastern time to discuss computed tomography screening for lung cancer. To register, go to http://www.ihi.org/AuthorintheRoom.

JAMA PATIENT PAGE

For your patients: Information about treatment of varicose veins.

See Article

First Page Preview

View Large
First page PDF preview

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.